- Home
- HCI vs AGIO Comparison
HCI vs AGIO Comparison
Compare HCI & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HCI | AGIO |
|---|---|---|
| Founded | 2006 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.3B |
| IPO Year | 2008 | 2013 |
Fundamental Metrics
Financial Performance| Metric | HCI | AGIO |
|---|---|---|
| Price | $182.65 | $33.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $230.00 | $38.88 |
| AVG Volume (30 Days) | 142.7K | ★ 1.2M |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | ★ 1.03% | N/A |
| EPS Growth | ★ 155.57 | N/A |
| EPS | ★ 11.05 | N/A |
| Revenue | ★ $900,946,000.00 | $43,011,000.00 |
| Revenue This Year | $11.44 | $76.75 |
| Revenue Next Year | $7.67 | $170.73 |
| P/E Ratio | $16.68 | ★ N/A |
| Revenue Growth | ★ 20.12 | N/A |
| 52 Week Low | $144.75 | $22.24 |
| 52 Week High | $210.50 | $46.00 |
Technical Indicators
Market Signals| Indicator | HCI | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 55.36 | 47.68 |
| Support Level | $183.13 | $26.71 |
| Resistance Level | $197.92 | $36.07 |
| Average True Range (ATR) | 5.18 | 1.69 |
| MACD | 0.01 | 0.10 |
| Stochastic Oscillator | 37.09 | 64.17 |
Price Performance
Historical ComparisonAbout HCI HCI Group Inc.
HCI Group Inc is engaged in the property and casualty insurance business through two Florida domiciled insurance companies, Homeowners Choice Property & Casualty Insurance Company (HCPCI) and TypTap Insurance Company (TypTap). Both HCPCI and TypTap are authorized to underwrite various homeowners' property and casualty insurance products and allied lines business in the state of Florida and other states. The operating segments of the group are insurance operations, TypTap Group, reciprocal exchange operations, real estate operations, and corporate and other. It derives key revenue from the HCPCI Insurance operation segment.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.